Skip to main content
SpringerLink
Log in

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177–1184.

    CAS  Google Scholar 

  2. Pettitt AR, Matutes E, Oscier D . Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20: 1441–1445.

    Article  CAS  Google Scholar 

  3. Auer RL, Gribben J, Cotter FE . Emerging therapy for chronic lymphocytic leukaemia. Br J Haematol 2007; 139: 635–644.

    Article  CAS  Google Scholar 

  4. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomized controlled trial. Lancet 2007; 370: 230–239.

    Article  CAS  Google Scholar 

  5. Best OG, Gardiner AC, Majid A, Walewska R, Austen B, Skowronska A et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008; 22: 1456–1459.

    Article  CAS  Google Scholar 

  6. Zenz T, Trbusek M, Smardova J, Häbe S, Denzel T, Malcikova J et al. P53 inactivation in CLL: pattern of 110 TP53 mutations. Blood (ASH Annual Meeting Abstracts), 2007; 110: 2064.

    Google Scholar 

  7. Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK . Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007; 109: 4424–4431.

    Article  CAS  Google Scholar 

  8. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Biology and Cytogenetics, Royal Bournemouth Hospital, Bournemouth, UK

    O G Best, A C Gardiner, Z A Davis, I Tracy, R E Ibbotson & D G Oscier

  2. MRC Toxicology Unit, University of Leicester, Leicester, UK

    A Majid

  3. Department of Haematology, University Hospitals, Leicester, UK

    M J S Dyer

Authors
  1. O G Best
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A C Gardiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z A Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Tracy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R E Ibbotson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Majid
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M J S Dyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D G Oscier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D G Oscier.

Additional information

Supplementary Information accompanies the paper on the Leukaemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Best, O., Gardiner, A., Davis, Z. et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 23, 212–214 (2009). https://doi.org/10.1038/leu.2008.260

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.260

  • Springer Nature Limited

This article is cited by

Search

Navigation